Fortress Biotech Business Summary

Fortress Biotech, Inc. (FBIO) operates as a biopharmaceutical business incubator and holding company that generates revenue through a diversified model of prescription product sales, royalty streams, equity stakes, and milestone payments. The company’s operations are segmented into dermatology—primarily through its majority-owned subsidiary Journey Medical Corporation—oncology, and rare diseases. Fortress employs a "hub-and-spoke" strategy, acquiring and advancing pharmaceutical assets through its subsidiaries to minimize early-stage R&D risk, a model recently validated by the January 2026 FDA approval of ZYCUBO® and the subsequent $205 million sale of its Rare Pediatric Disease Priority Review Voucher. Within the market, Fortress competes with biotechnology aggregators and royalty-based firms such as XOMA Royalty, Myriad Genetics, Vanda Pharmaceuticals, and Verastem Oncology, distinguishing itself as a high-velocity asset acquirer with a portfolio of nine marketed products and over 25 programs in development. The executive leadership is led by Chairman, President, and CEO Dr. Lindsay A. Rosenwald, M.D., a veteran biotech financier and former Chairman of Paramount BioCapital who has overseen the founding of numerous successful life sciences ventures. Key leadership includes Michael S. Weiss, Executive Vice Chairman of Strategic Development, and David Jin, who serves as Chief Financial Officer and Head of Corporate Development with prior experience at Barings and Sorrento Therapeutics. The company’s governance is supported by a board of directors that includes Malcolm Hoenlein and Dov Klein, CPA, while its financial stability is backed by notable institutional partners and lenders such as Hercules Capital and Oaktree Capital Management. This team leverages deep industry pedigree to manage a complex network of subsidiaries, including Mustang Bio and Avenue Therapeutics, focusing on maximizing shareholder value through aggressive asset monetization and commercial execution.